What one share of vTv Therapeutics holds
We are a late-stage biopharmaceutical company focused on developing orally administered therapies for metabolic and inflammatory diseases with the goal of improving patient outcomes. Our lead product candidate, cadisegliatin (TTP399), is a novel, small-molecule, liver-selective glucokinase activator (GKA) currently being evaluated in a Phase 3 clinical trial as a potential oral adjunctive therapy to insulin for the treatment of type 1 diabetes (T1D).
vTv Therapeutics’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Sales | $2.97 |
|---|---|
| Profit | −$0.38 |
| Cash and investments | $6.97 |
| Book value | $6.32 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2021 | $2.56 | −$8.29 | $0.00 | −$12.32 | — | — |
| 2022 | $1.05 | −$9.98 | $0.01 | −$8.35 | — | −$5.59 |
| 2023 | $0.00 | −$9.71 | $0.00 | −$9.15 | — | −$11.83 |
| 2024 | $0.18 | −$3.20 | $0.00 | −$4.39 | — | $2.11 |
| 2025 | $0.00 | −$3.20 | — | — | — | $7.64 |
Common questions about vTv Therapeutics
How much does one share of vTv Therapeutics earn?
Over the last 12 months, vTv Therapeutics lost $0.38 for each share on $2.97 of sales.
Does vTv Therapeutics pay a dividend?
vTv Therapeutics didn’t pay a dividend over the last 12 months, according to its SEC filings.
What is vTv Therapeutics’s book value per share?
vTv Therapeutics’s book value is $6.32 per share: what would be left for each share if it sold everything at the values on its books and paid every debt, as of June 30, 2026.
How much cash and debt does each share of vTv Therapeutics have?
Each share of vTv Therapeutics has $6.97 of cash and investments, as of June 30, 2026.
Has vTv Therapeutics bought back shares?
vTv Therapeutics’s share count rose about 438% from 2021 to 2025. That dilution means each share owns a smaller slice of the company.
From its SEC filings. For education only, not investment advice. New to these words? See the StockSlicer glossary.